Skip to main
MLTX
MLTX logo

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake Immunotherapeutics (MLTX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 40%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

MoonLake Immunotherapeutics is advancing a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, SLK, which has demonstrated promising efficacy in clinical trials, particularly in treating hidradenitis suppurativa (HS) and potentially other inflammatory conditions. The positive feedback from key opinion leaders suggests a strong likelihood of superior outcomes in upcoming Phase III trials, supported by the drug's efficacy data compared to established therapies like Cosentyx. Additionally, with HS presenting a significant unmet medical need and rising awareness, there exists potential for substantial market opportunities, bolstered by revenues from other indications such as psoriatic arthritis (PsA).

Bears say

MoonLake Immunotherapeutics faces significant risks that contribute to a negative outlook on its stock, primarily tied to the clinical and regulatory pathways of its lead asset, SLK. Any unforeseen safety issues, suboptimal efficacy results, or pharmacokinetic challenges could hinder ongoing clinical trials, reducing the prospects for success and revenue generation. Furthermore, the company reported a substantial net loss of $44.2 million in the fourth quarter of 2024, and key issues such as inconsistent dose dependency in clinical trials and potential difficulties entering the market against established competitors further exacerbate concerns regarding its financial viability.

MoonLake Immunotherapeutics (MLTX) has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 40% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MoonLake Immunotherapeutics (MLTX) Forecast

Analysts have given MoonLake Immunotherapeutics (MLTX) a Buy based on their latest research and market trends.

According to 15 analysts, MoonLake Immunotherapeutics (MLTX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MoonLake Immunotherapeutics (MLTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.